New drug cocktail aims to stop head and neck cancer from coming back
NCT ID NCT07632339
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether giving a combination of two drugs—Becotatug Vedotin (a targeted chemotherapy) and Pucotenlimab (an immunotherapy)—before and after surgery can improve outcomes for people with recurrent head and neck cancer that can still be removed. About 102 participants will either receive the drug combo then surgery, or surgery alone followed by standard care. The main goal is to see if the combo helps patients live longer without the cancer returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Becotatug Vedotin (a targeted chemotherapy) combined with Pucotenlimab (an immunotherapy)
What this could lead to
If successful, this combination could become a new standard approach to shrink tumors before surgery and reduce the chance of cancer returning in patients with recurrent head and neck cancer.
What could go wrong
This is a Phase II trial with only 102 participants, so results are preliminary. The combination may cause significant side effects, and not all patients may benefit—some might still need standard treatment after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••